PNPLA3

PNPLA3 (patatin-like phospholipase domain-containing protein 3) is an enzyme that resides on lipid droplets inside liver cells, where it participates in the remodeling of stored triglycerides. A common genetic variant of this protein, known as I148M, is one of the strongest known genetic risk factors for fatty liver disease. Carriers of this variant accumulate excess fat in the liver, and over time this is associated with inflammation, fibrosis (scarring), cirrhosis, and increased risk of liver cancer. The biological rationale for modulating PNPLA3 is that reducing the amount of the dysfunctional protein produced in liver cells should relieve the abnormal lipid handling it causes, potentially slowing or reversing the buildup of fat and downstream liver injury. This mechanism is broadly relevant to non-alcoholic fatty liver disease and its more severe form, non-alcoholic steatohepatitis, as well as alcohol-related liver disease, where PNPLA3 variants worsen outcomes. Because the pathogenic effect stems from a toxic accumulation of the mutant protein rather than simple loss of a needed function, lowering overall PNPLA3 expression in the liver, rather than trying to restore normal enzyme activity, is a rational therapeutic strategy. One such approach uses a technology designed to reduce the genetic message that produces this protein specifically within liver cells.